FibroBiologics produces third batch of experimental cell therapy for diabetic foot ulcers
FibroBiologics completed manufacturing of a third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers. The batch was produced under cGMP standards and is undergoing required safety and quality testing ahead of release for clinical use. Upo
<p>FibroBiologics completed manufacturing of a third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers. The batch was produced under cGMP standards and is undergoing required safety and quality testing ahead of release for clinical use. Upo</p>